About Us

SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 (Suciraslimab) is a potential global first-in-class mAb against CD22 for the treatment of rheumatoid arthritis and has completed Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Thirteenth Five-Year Plan Period. SM03 has met its primary endpoint in its Phase III clinical study for the treatment of rheumatoid arthritis (RA) in China in April 2023. On 5 September 2023, the National Medical Products Administration of the People's Republic of China has accepted the biologics license application (BLA) for SM03 (Suciraslimab) in the treatment of RA.

 

Product Pipeline


sm03hover11-11

Core Product


Anti-CD22


First-in-Class

sn11h

NCE
Drug Candidate

BTK Inhibitor


Third-Generation

sm17hover11-11

Biologic Candidates


Humanized monoclonal antibody targeting the receptor for IL-25


First-in-Class

sm09h





Humanized Anti-CD20

sm06hover11-11





Humanized Anti-CD22


What's News



Our Office